GlassScriptPhysician profile
Patrina Lockette
NPI 1508899907
$4,655.36
in general payments reported to CMS, 2019-2025
33 companies · $803 in 2025
The $803 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $354 · 2020: $231 · 2021: $514 · 2022: $793 · 2023: $849 · 2024: $1,111 · 2025: $803.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,763.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,762.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $899.55 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $776.36 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $508.99 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $400.87 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $279.90 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $265.12 | 2019-2025 | Jardiance, Ofev |
| Astellas Pharma US INC | $213.77 | 2020-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $179.63 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $148.59 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $123.63 | 2019-2024 | |
| Abbvie INC. | $116.99 | 2021-2025 | |
| Amgen INC. | $98.48 | 2019-2025 | Repatha, Otezla, Repatha |
| Abbott Laboratories | $90.17 | 2021-2024 | Freestyle Libre 3 |
| Exact Sciences Corporation | $71.51 | 2023-2025 | Cologuard Collection Kit |
| Corcept Therapeutics | $71.08 | 2024-2025 | Korlym |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $56.71 | 2019-2024 | Verquvo, Belsomra, Steglatro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.13 | 2023 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $29.76 | 2022-2024 | Eliquis |
| Antares Pharma, INC. | $24.78 | 2024 | Xyosted |
| Gilead Sciences, INC. | $23.77 | 2025 | Biktarvy |
| Xeris Pharmaceuticals, INC. | $23.49 | 2022 | |
| Viiv Healthcare Company | $22.71 | 2025 | Dovato |
| Phathom Pharmaceuticals, INC. | $22.59 | 2025 | Voquezna |
| Biohaven Pharmaceutical Holding Company LTD. | $20.16 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $20.04 | 2025 | Zoryve |
| Dexcom, INC. | $19.80 | 2025 | Dexcom G6 Transmitter |
| Ferring Pharmaceuticals INC. | $19.21 | 2023 | Rebyota |
| Sumitomo Pharma America, INC. | $18.81 | 2025 | Gemtesa |
| Amarin Pharma, INC. | $17.74 | 2020 | |
| Boston Scientific Corporation | $17.65 | 2022 | |
| Idorsia Pharmaceuticals US INC | $15.33 | 2023 | Quviviq |
| Avanir Pharmaceuticals, INC. | $13.76 | 2021 | |
| Genentech USA, INC. | $13.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrina Lockette listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.